Casdin Capital
No summary available yet.
Casdin is the rare life sciences fund where the founder actually knows what he's talking about - Eli wrote a prescient book on molecular medicine in 2011 and has been right about precision medicine disrupting healthcare. With $2.4B AUM and a track record including 38 IPOs and 6 unicorns, they're serious players who can write big checks and open doors. The catch? Eli is a one-man show and notoriously picky - he'll grill you on the science and business model until your head spins. They move slow (this is biotech after all) but when they commit, they're genuinely helpful with regulatory strategy and customer intros. Fair warning: they expect founders to be as obsessed with the data as they are.
- —Best for: Series B+ life sciences companies with real IP and regulatory pathway
- —Watch out for: Extremely technical diligence process - know your science inside out
- —Known for: Deep sector expertise and ability to help navigate FDA/regulatory hurdles
Great medicines make great investments, and Casdin Capital invests in all aspects of today's Life Sciences revolution. The companies we work with are putting to use the incredible knowledge base unlocked by the accelerating capability to read and manipulate molecular information. They focus on precision medicine and molecular approaches that are transforming healthcare.
Casdin Capital has made 51 investments in Series B stage with an average round size of $82M, 40 investments in Series A stage with an average round size of $59.9M and 15 investments in Series C stage with an average round size of $107M. Primary focus on life sciences, biotechnology, genomics, synthetic biology, with some digital health and agtech investments.
Focused on emergent technologies in life sciences for more than two decades, Eli has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the life sciences and healthcare industries. Prior to founding Casdin Capital, he served as vice president at Alliance Bernstein's thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there he co-authored the 2011 black book The Dawn of Molecular Medicine. Columbia MBA, sits on boards of GeneDx and Standard BioTools.
Have a specific question about Casdin Capital?
Ask Bernie →